Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment of Certain Patients with Chronic Hep C Genotypes 1, 3 and 4

Bristol-Myers Squibb BMY today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4. Approximately 214,000 people in the UK are thought to have chronic HCV, and roughly 100,000 of those patients are estimated to have genotype 3, a difficult-to-treat and often aggressive form of chronic HCV. "It is a challenge to treat patients with hepatitis C virus infection, including the See full press release